For peanut allergy sufferers, relief could be on the way. Luis salmun, md, vp, medical affairs, north america, dbv technologies, discussed results from the viaskin peanut study and explained the patch could be a. Biopharmaceutical food allergy treatments dbv technologies. Dbv technologies, creator of viaskin, a new paradigm for the treatment of food allergies, and the consortium of food allergy research cofar announced today that enrollment into the cofar6 study, a multicenter, randomized, doubleblinded, placebocontrolled phase ii clinical trial of viaskin peanut for the treatment of peanut allergic. An ongoing trial to further evaluate peanut epit is sponsored by nihs national institute of allergy and infectious diseases niaid and conducted by the niaidfunded consortium of food allergy research cofar. The researchers tried varying patch doses to see which was most effective. Studies were scarce, and it felt like we had won the lottery. Inside each patch is a sprayedon sample of peanut protein. So when a few months later, in september of 20, we received a call from new yorks mount sinai hospital, and josh was offered a place in the viaskin peanut patch study, we jumped at the chance. The viaskin peanut patch, worn for a year by peanut allergic children and adults, appears to educate cells to turn off the allergic reaction, said lead researcher dr. Peanut allergy is the most common lifethreatening food allergy, with an overall prevalence of 0. Dbv technologies launches phase 3 trial for viaskin.
Objective to assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut allergic children. Nov 03, 2016 the viaskin peanut patch offers an alternative to the oral intake method, which has certainly proven to be a more viable method of peanut protein delivery. Despite study setback, hope remains for viaskin peanut patch. This is the first time that a drug for food allergy has reached phase iii a step in the clinical trial process during which a drug. Jun 24, 20 the viaskin peanut patch could end the immune systems lifethreatening response to peanut protein by introducing trace amounts into the outer layer of skin. The treatment, called epicutaneous immunotherapy or epit, was safe and welltolerated. Perhaps once the us food and drug administration approves this patch, peanut allergy resistance development via this method will be more widely accepted. Viaskin peanut phase iii trial falls short, still chance for. Viaskin epicutaneous immunotherapy dbv technologies. Half of the patients who wore the 250 g peanut patch daily for 1 year, were able to tolerate at least 1 gram of peanut protein that is about 4 peanuts. Viaskin peanut allergy patch fast tracked by fda achoo. The viaskin peanut patch made by the french biotech firm dbv technologies boosted the amount of. According to an article in healthday news the viaskin peanut patch, worn for a year by peanutallergic children and adults, appears to educate cells to turn off the allergic reaction, said lead researcher dr. This study evaluates the safety of viaskin peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age.
Skin patch could treat peanut allergy national institutes. The viaskin peanut patch offers an alternative to the oral intake method, which has certainly proven to be a more viable method of peanut protein delivery. Dbv technologies peanut allergy treatment wins fda. Skin patch to treat peanut allergy shows benefit in children. Additionally, viaskin peanut received breakthrough and fast track designation from the fda in 2015 and 2012, respectively. Dbv technologies announces topline results of phase iii. Spencer now wears a patch, called the viaskin peanut, that releases a little bit of peanut protein into his skin. Design, setting, and participants phase 3, randomized, doubleblind, placebocontrolled trial conducted at 31 sites in 5 countries between january 8, 2016, and august 18, 2017. In an interview with md magazine at aaaai 2019, edwin kim, md, ms, of university of north carolina school of medicine, elaborated on what a suddenly viable market could mean for treating food allergy.
A wearable patch used to treat peanut allergies has shown tremendous promise in a recently concluded clinical trial, performing particularly well among young children. The viaskin peanut patch could end the immune systems lifethreatening response to peanut protein by introducing trace amounts into the outer layer of skin. In our preclinical trials, viaskin was evaluated to determine if it provided allergenic information to the immune system. Patients were randomized into four treatment arms to evaluate three doses of viaskin peanut, 50. In december 2015, the patch entered a phase 3 trial, which will set the company up for the fda to decide whether it wants to approve. The future of the peanut patch immunotherapy treatment is uncertain after a phase 3 trial failed to meet its main statistical goal. Nov 01, 2016 theres a patch that could fix your peanut allergy problem. The coinsize viaskin patch, worn daily on the skin, helps reduce peanut sensitivity through gradual exposure, its.
Dbv technologies, the french company that developed the viaskin peanut patch, announced in october that while 35. Safety study of viaskin peanut to treat peanut allergy full. Phase iii trials are currently underway in peanut allergic children four to 11 years of age. Theres a patch that could fix your peanut allergy problem. Peanut patch boiled peanuts original, cajun and spicy. Viaskin peanut patch pepites press release viaskin peanut patch phase iii pepites highlights. A skin patch to treat peanut allergies just passed a crucial test. Dbv is expanding the viaskin peanut trial to include more patients, more centers, and more countries.
Viaskin peanut allergy treatment pipeline dbv technologies. Viaskin patch shows promise for peanutallergic children. The viaskin peanut patch made by the french biotech firm dbv technologies was granted a breakthrough therapy designation by the federal food and drug administration that status is. A promising peanut allergy treatment tested by seattle area doctors entered phase iii trials at the end of 2015. Dbv technologies are making good progress in the development of their skinpatch peanut allergy therapy product viaskin peanut. The viaskin peanut therapy has a robust set of clinical data behind it. The viaskin patch was proven to be safe and increased childrens ability to tolerate peanuts in a finalstage study, but the company said in october the results fell short of the trials main statistical goal. The treatment, called epicutaneous immunotherapy or epit, was safe and welltolerated, and nearly all participants used the skin patch. Safety study of viaskin peanut to treat peanut allergy.
Vipes viaskin peanut s efficacy and safety vipes viaskin peanut s efficacy and safety was a doubleblind, placebocontrolled, multicenter clinical trial conducted at 22 sites in north america and europe that enrolled 221 patients. In the first half of 2015, dbv began preclinical work for viaskin egg, with the goal of initiating a clinical program if these studies are successful. Viaskin peanut is a novel form of allergy immunotherapy in development. This friday, dbv technologies issued a press release summarizing the top line results of the phase iii trial of their viaskin peanut patch therapy. Epicutaneous immunotherapy for the treatment of peanut allergy in. Mar 18, 2015 researchers with the jaffe food allergy institute at kravis childrens hospital at mount sinai may have a solution. Viaskin peanut for the treatment of peanut allergy. Peanut patch gives 11yearold allergy sufferer a little bit. The viaskin patch was proven to be safe and increased childrens ability to tolerate peanuts in a finalstage study, but the company said in october the results fell short of the trials main. A new treatment aims to desensitize patients to peanut allergies.
The fda has awarded breakthrough therapy designation for peanut allergy treatment to dbv technologies viaskin peanut. The pepites study evaluates the efficacy and safety of viaskin peanut 250 g peanut protein to induce desensitization to peanut in peanut allergic children 4 through 11 years of age after a 12month treatment by epicutaneous immunotherapy epit. Publications home of jama and the specialty journals of the. Peanut allergy occurs in 1 2% of people in the united states and other western countries. A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to oneyear results from an ongoing clinical trial. Topline results show a statistically significant response with a favorable tolerability profile, with 35. Dec 22, 2015 the pepites study evaluates the efficacy and safety of viaskin peanut 250 g peanut protein to induce desensitization to peanut in peanutallergic children 4 through 11 years of age after a 12month treatment by epicutaneous immunotherapy epit. Epicutaneous immunotherapy for the treatment of peanut. Subjects apply placebo viaskin patch daily for a 52week blinded period.
Nov 16, 2017 the future of the peanut patch immunotherapy treatment is uncertain after a phase 3 trial failed to meet its main statistical goal. Efficacy and safety of several doses of viaskin peanut in adults and. Efficacy and safety of viaskin peanut in peanutallergic children. A new study says the allergy patch viaskin is showing promise. Over 450 patients have been treated in 5 clinical randomized, placebocontrolled, multicenter clinical trials. Viaskin egg is a product under preclinical development and has not been approved for any use in any country, including. Dbv technologies submits biologics license application to u.
Jan 19, 2016 in april 2015, the viaskin peanut patch made by french company dbv technologies was awarded a breakthrough therapy designation by the u. Peanut skin patch may be boon for allergy sufferers, study finds. Viaskin peanut allergy treatment healthy wearable skin patch. The viaskin peanut patch, worn for a year by peanutallergic children and adults, appears to educate cells to turn off the allergic reaction, said lead researcher dr.
Though the therapy showed a statistically significant level of improvement over placebo, it fell shy of the efficacy intended to support fda approval. Subjects will receive either viaskin peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment. In december 2015, the patch entered a phase 3 trial, which will set the company up for the fda to. Pepites is expected to enroll approximately 330 patients in about 30 centers across north america canada and the united states, europe, and. It marks the first time the fda granted the designation for a food allergy, the francebased company says. Luis salmun, md, vp, medical affairs, north america, dbv technologies, discussed results from the viaskin peanut study and explained the patch could be a potential treatment for children with peanut allergies. The patch, named viaskin, delivers small amounts of peanut protein through the skin.
Peanut epicutaneous phase ii immunotherapy clinical trial full. Published in the journal of allergy and clinical immunology, the study found almost half of the subjects that used the viaskin peanut patch for 12 months could intake 10 times more peanut protein than they could prepatch. Peanut patch for allergy sufferers goes to phase iii trial iths. Viaskin peanut allergy patch fast tracked by fda april, 2015 kevvyg over the last few years there has been a lot of good starts when it comes to novel treatments of allergies and asthma. The new study involved 221 people, ages 6 to 55, with peanut allergy. Dbv technologies announces fda acceptance of bla filing for viaskin peanut for the treatment of peanut allergy. In addition, some participants were given a placebo.
Dbv technologies start phase iii trials with their peanut. Stephen tilles with the seattle food allergy consortium is the seattlearea. Viaskin peanut peanut allergy immunotherapy dbv 712. Phase iii trials are currently underway in peanutallergic children four to 11 years of age. Peanut allergy is common, lifethreatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy epit by using viaskin peanut for peanut allergy. Feb 14, 2018 the viaskin patch was proven to be safe and increased childrens ability to tolerate peanuts in a finalstage study, but the company said in october the results fell short of the trials main. Apr 14, 2015 the viaskin peanut patch made by the french biotech firm dbv technologies was granted a breakthrough therapy designation by the federal food and drug administration that status is granted to. We evaluated peanut epicutaneous immunotherapy epit by using viaskin peanut for peanut allergy treatment.
Feb 25, 2015 the viaskin patch was place on the upper arm. Feb 23, 2015 according to sampson, the new viaskin patch works by exposing users to a controlled amount of peanut allergen in hopes of increasing their tolerance. Dbv technologies reports march 31, 2020 cash position download pdf kb 2020. Big news for campers interested in a treatment for peanut. Phase i trials tested 3 doses of the patch 50, 100, 250g against a placebo on 100 subjects 650 years of age. Skin patch to treat peanut allergy shows benefit in. Dbv technologies reports december 31, 2015, cash position. Hugh sampson, director of the jaffe food allergy institute at. Efficacy and safety of viaskin peanut in children with. Peanut allergies are particularly devastating, as even trace amounts of peanuts can cause devastating effects like anaphylactic shock and death. The patch is designed to deliver biologically active compounds to the immune system through the skin. The allergens are given to trigger an effect in the immune system with the aim of desensitising an allergy sufferer to. Viaskin patch, peanut allergy patch, treatment for peanut.
Mar 27, 2017 dbv technologies are making good progress in the development of their skin patch peanut allergy therapy product viaskin peanut. Peanut skin patch may be boon for allergy sufferers, study. Viaskin peanut, which is based on epicutaneous immunotherapy epit. There are no approved immunotherapies for food allergies. Dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports september 30, 2019 cash position. Viaskin peanut patch could be the answer to peanut. Peanut patch shows promise in latest clinical trial. Once applied to skin, viaskin was designed to create a condensation chamber that hydrates the skin and solubilizes the allergen allowing it to penetrate the epidermis. Oct 26, 2016 a wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to oneyear results from an ongoing clinical trial.
Theres a patch that could fix your allergy problem. Alerts and advisories rss feeds trends, charts, and maps downloading content for analysis. Dbv technologies provides update on viaskin peanut bla for children ages 411. For most patients, about 12 peanut is likely to trigger symptoms. Hope remains for the viaskin peanut patch allergic living. The new patch works by delivering small doses of peanut protein through the users skin and into their body. In the viaskin peanuts efficacy and safety vipes study, 221 subjects 655 years of age were randomized to a 50. Nov 01, 2016 the new patch works by delivering small doses of peanut protein through the users skin and into their body.
Dbv technologies announces fda acceptance of bla filing for. Dbv technologies announces results of its 2020 ordinary and extraordinary general meeting download pdf 201 kb 2020. In april 2015, the viaskin peanut patch made by french company dbv technologies was awarded a breakthrough therapy designation by the u. Peanut patch to treat allergy in the works medscape. Peanut patch boiled peanuts go from land to canned in 24 hours, so you enjoy the freshest snack possible. Researchers with the jaffe food allergy institute at kravis childrens hospital at mount sinai may have a solution. Will this new skin patch put an end to peanut allergies. Sep 27, 2016 this study evaluates the safety of viaskin peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Mar 29, 2011 a new treatment aims to desensitize patients to peanut allergies. Epicutaneous immunotherapy epit is effective and safe to. A patch worn on intact skin is used to deliver peanut allergens.
239 1095 744 37 52 776 1306 1529 1639 1477 1558 290 373 802 740 1514 328 257 1327 698 836 644 78 524 304 273 604 233 559 1046 1376 678 767 473 246 226 1023 968